Weiwei Qi

2.4k citations
106 papers · 1.8k indexed · h-index 26

Weiwei Qi

99 papers receiving 1.7k citations

Peers

Weiwei Qi
Comparison fields: 5 of 109
  • Immunology and Allergy 106
  • Cancer Research 263
  • Hematology 181
  • Immunology 286
  • Rehabilitation 83
Replace B. Caramés with:
B. Caramés Spain
Chi Dae Kim South Korea
Tatsuki Itoh Japan
Andrea Hartner Germany
Norifumi Urao United States
Shan‐Chi Liu Taiwan
Hui Fang China
Qinghong Zhang China
Tianlun Yang China
Weiwei Qi relative to B. Caramés Spain B. Caramés's profile →
Citations per field
00.5×4.5×
B. Caramés · 1×
Citations per year

Countries citing papers authored by Weiwei Qi

Since Specialization
Citations

This map shows the geographic impact of Weiwei Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Qi more than expected).

Fields of papers citing papers by Weiwei Qi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiwei Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Qi. The network helps show where Weiwei Qi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Weiwei Qi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Weiwei Qi Line = papers co-authored together Weiwei Qi links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 20250
4 20241
5 202414
6 20243
7 20232
8 20232
9 20233
10 20236
11 20231
12 202058
13 201837
14
Clinical effect of the concomitant administration of bevacizumab with docetaxel, 5-FU, and cisplatin on advanced gastric cancer
20171
15 20166
16 201613
17 20148
18 201430
19 20121
20 201217

About Weiwei Qi

Weiwei Qi is a scholar working on Hematology, Immunology and Allergy, Immunology, Biological Psychiatry and Cancer Research, having authored 106 papers that have together received 1.8k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (10 papers), Immune Cell Function and Interaction (9 papers), Cell Adhesion Molecules Research (8 papers), Platelet Disorders and Treatments (6 papers), FOXO transcription factor regulation (6 papers), Angiogenesis and VEGF in Cancer (6 papers), Cancer Mechanisms and Therapy (6 papers) and Immune cells in cancer (6 papers). The work is most often cited by research in Immunology and Allergy (106 citations), Cancer Research (263 citations), Hematology (181 citations), Immunology (286 citations) and Rehabilitation (83 citations). Weiwei Qi has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Ti Zhou, Zhonghan Yang, Xia Yang, Guoquan Gao, Guoquan Gao, Juan Feng, Gaston Vilaire, Jing Lv, Joel Bennett and Wensheng Qiu. Their work appears in journals such as International Journal of Hematology, Frontiers in Immunology, Oncology Reports, Biochemical and Biophysical Research Communications and Nephrology Dialysis Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026